These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 1969668)
61. Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats. Lau YS; Fung YK; Anderson TM Gen Pharmacol; 1997 Nov; 29(5):729-36. PubMed ID: 9347318 [TBL] [Abstract][Full Text] [Related]
62. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia. Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430 [TBL] [Abstract][Full Text] [Related]
63. Dopamine receptors and the dopamine hypothesis of schizophrenia. Seeman P Synapse; 1987; 1(2):133-52. PubMed ID: 2905529 [TBL] [Abstract][Full Text] [Related]
64. Infra-additivity of combined treatments with selective D1 and D2 receptor antagonists for inhibiting sucrose reinforcement. Schneider LH; Watson CA; Gibbs J; Smith GP Brain Res; 1991 May; 550(1):122-4. PubMed ID: 1832327 [TBL] [Abstract][Full Text] [Related]
65. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity. Ben-Shachar D; Youdim MB J Neurochem; 1990 Apr; 54(4):1136-41. PubMed ID: 1968955 [TBL] [Abstract][Full Text] [Related]
66. Two distinct classes of dopamine receptor mediating actions of antipsychotics: binding and behavioral studies. Sokoloff P; Martres MP; Protais P; Costentin J; Schwartz JC Adv Biochem Psychopharmacol; 1983; 36():163-73. PubMed ID: 6134435 [No Abstract] [Full Text] [Related]
67. Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat. Fletcher GH; Starr MS Eur J Pharmacol; 1987 Jun; 138(3):407-11. PubMed ID: 2957221 [TBL] [Abstract][Full Text] [Related]
68. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. Tarazi FI; Zhang K; Baldessarini RJ J Pharmacol Exp Ther; 2001 May; 297(2):711-7. PubMed ID: 11303062 [TBL] [Abstract][Full Text] [Related]
69. The mechanism of action of novel antipsychotic drugs. Meltzer HY Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253 [TBL] [Abstract][Full Text] [Related]
70. Intact discrimination reversal learning but slowed responding to reward-predictive cues after dopamine D1 and D2 receptor blockade in the nucleus accumbens of rats. Calaminus C; Hauber W Psychopharmacology (Berl); 2007 Apr; 191(3):551-66. PubMed ID: 17021925 [TBL] [Abstract][Full Text] [Related]
71. Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer. Phillips GD; Robbins TW; Everitt BJ Psychopharmacology (Berl); 1994 Mar; 114(2):345-59. PubMed ID: 7838928 [TBL] [Abstract][Full Text] [Related]
72. Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats. Levin ED Behav Neural Biol; 1988 Sep; 50(2):240-5. PubMed ID: 2906537 [TBL] [Abstract][Full Text] [Related]
73. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats. Glavan G; Sket D; Zivin M Mol Pharmacol; 2002 Feb; 61(2):360-8. PubMed ID: 11809861 [TBL] [Abstract][Full Text] [Related]
74. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity. Scatton B J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430 [No Abstract] [Full Text] [Related]